Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer

Journal of the National Cancer Institute

Volumn 87, Issue 10, 1995, Pages 751-756

  Foekens, John A ^a   Look, Maxime P ^a   Peters, Harry A ^a   Van Putten, Wim L J ^a   Portengen, Henk ^a   Klijn, Jan G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE RECEPTOR; TAMOXIFEN; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029021196     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.10.751     Document Type: Article

References (29)

1. Vassalli JD, Baccino D, Belin D: A cellular binding site for the Air 55,000 form of the plasminogen activator, urokinase. J Cell Biol 100;86-92, 1985
2. Cubellis MV, Nolli ML, Cassani G, et al: Binding of single-chain prourokinase receptor to human U937 cells. J Biol Chem 261:15819-15822,1986
3. Ellis V, Behrendt N, Danp K: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752-12758, 1991
4. Liotta LA, Goldfarb RH, Brundage R, et al: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636, 1981
5. Dano K, Andreasen PA, Grpndahl-Hansen J, et al: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985
6. Andreasen PA, Georg B, Lund LR, et al: Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68:1-19, 1990
7. Ellis V, Wun TC, Behrendt N, et al: Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J Biol Chem 265:9904-9908, 1990
8. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1 EMBOJ 9:1079-1085, 1990
9. Olson D, Pdllanen J, Hoyer-Hansen G, et al: Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267:9129-9133,1992
10. Duffy MJ, O’Grady C, Devaney D, et al: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62:531-533, 1988
11. Duffy MJ, Reilly D, O’Sullivan C, et al: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829, 1990
12. Janicke F, Schmitt M, Hafter R, et al: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69-78, 1990
13. Foekens JA, Schmitt M, van Putten WL, et al: fhognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
14. Spyratos F, Martin PM, Hacène K, et al: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
15. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521,1993.
16. Janicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17:303-312, 1991
17. Janicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
18. Bouchet C, Spyratos F, Martin PM, et al: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69:398-405, 1994
19. Foekens JA, Schmitt M, van Putten WL, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658,1994
20. Foekens JA, Portengen H, Look MP, et al: Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70:1217-1223, 1994
21. Nicholson S, Sainsbury JR, Halcrow JR, et al: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1:182-185, 1989
22. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
23. Barlow RE, Bartholomew DJ, Bremmer JM, et al: Statistical Interference Under Order Restrictions. London: Wiley, 1972
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Nicholson RI, McClelland RA, Gee JM, et al: Transforming growth factor-a and endocrine sensitivity in breast cancer. Cancer Res 54:1684-1689,1994
26. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121,1992
27. Dickson RB: Stimulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Mol Biol 37:795-803, 1990
28. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
29. Horwitz KB: Cellular heterogeneity and mutant oestrogen receptors in hormone resistant breast cancer. Cancer Surv 14:41-54, 1992